Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New faces join Stada’s top team

Executive Summary

Stada Arzneimittel has made several appointments to its management team to implement a “new strategic orientation” that will see the German group focus on the ‘three pillars’ of “generics, non-prescription brands and specialty pharmaceuticals such as biosimilars” as well as expand in emerging markets (Generics bulletin, 16 March 2018, page 1). Miguel Pagan – Sandoz’ head of global technical operations and former head in Europe and India – will join Stada’s executive board with responsibility for production and development, replacing Barthold Piening. Having joined Stada from Acino midway through last year (Generics bulletin, 27 January 2017, page 16), Piening’s membership of Stada’s executive board has been cancelled with immediate effect and he “will leave Stada at the end of May 2018 in order to pursue new career opportunities”.

You may also be interested in...

Wagner Adds Germany To Role As Stada Simplifies Structure

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

Keeping Track: StrataGraft Continues US FDA’s Biologic Center Approvals Streak; Another CRL For Avenue’s Tramadol IV

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

DTC Ads Might Inflate Medicare Drug Spending But Clear Cause-And-Effect Is Elusive, GAO Concludes

Sens. Durbin and Grassley hope report will help revive their flagging legislation that would require Rx ads to include list prices Senators claim that the Government Accountability Office concludes that direct-to-consumer spots for prescription drugs drives ‘drastic’ increases in Medicare costs.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts